A California federal judge has determined that biotech company Biogen owes Roche's Genentech more than $88 million in patent royalties for sales of Biogen's blockbuster multiple-sclerosis and Crohn's ...

A top boarding school has been ordered to pay £145,000 to a pupil who suffered a drug-induced breakdown after she was given drugs by senior boys at the school.

WASHINGTON -- An experimental medication made from marijuana successfully reduced back pain in a new study, offering further support for the drug’s potential in treating one of the most common forms ...

Deaths involving illicit ketamine use have soared twenty-fold since 2014, a new study has revealed. In what is the most detailed assessment of ketamine-related deaths to date, researchers found deaths ...

Speedy regime change in Venezuela has always been President Trump’s plan. It just didn’t work the last time.

Vidofludimus calcium currently is being evaluated in relapsing MS in two phase III trials, ENSURE-1 and ENSURE-2. The phase III trials in relapsing MS will further evaluate the effect of vidofludimus ...

TORONTO, Oct. 02, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (Upstream: QNTM) (“Quantum BioPharma” or the “Company”), a biopharmaceutical company dedicated ...

A Craighead County man arrested on a drug charge in 2024 that carries a maximum penalty of 20 years in prison pleaded guilty Tuesday in federal court to one count of possession of methamphetamine with ...

A combination of metformin, a common diabetes drug, and clemastine, an antihistamine, can help repair myelin—the protective coating around nerves, which gets damaged in multiple sclerosis (MS) causing ...

Affiliated with the UB Institute for Artificial Intelligence and Data Science, the lab allows Ramanathan and his interdisciplinary team to apply AI, deep learning, large language models, ...

Combining the diabetes medication metformin and the antihistamine clemastine increased myelin repair in people with RRMS, trial results show.

The company was expecting a decision from the FDA by Sept. 28 for its oral drug tolebrutinib, but an update to the drug’s application package convinced the agency to take more time to review.